Biotechnology major Biocon today said it has launched its cancer biosimilar drug KRABEVA in India. The biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India, Biocon said in a filing to the BSE. Biocon CEO and Joint MD Arun Chandav
EQL Pharma has signed a three-year cooperation agreement, with a possibility to extent, with a leading generic company regarding the drug Potassium chloride. EQL estimates that the profitability will be similar, whether EQL Pharma sells on its own or through the partner. Potassium chloride EQL Pharma is part of EQL Pharmas long-term commitment to s
By a News Reporter-Staff News Editor at Drug Week Mylan N.V. announced the U.S. launch of Clofarabine Injection, 20 mg/20 mL Single-Dose Vials, a generic version of Genzyme's Clolar . Mylan is one of the largest suppliers of cancer medicines by volume in the U.S., with a robust oncology portfolio of more than 40 products. Clofarabine Injection,
The United Kingdom`s National Institute for Health Research, part of the National Health Service, has created a website to educate the public about biosimilar drugs. The website, Focus on Biosimilars, explains the background of biologic drugs and the subsequent development of biosimilar drugs, which the NHS says, may well hold the key to ensuring t
By a News Reporter-Staff News Editor at Drug Week Generics Limited has been issued patent number 9808423, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. This patent was filed on October 12, 2005 and was published online on November 7, 2017. See Anthony Hickey, Pharmaceutical Inhalation Aerosol Technology,
RedHawk Holdings Corp. announced today its results for the three-month period ended September 30, 2017 as it continues to methodically build and develop its branded generic pharmaceutical and medical device business. For the three-month period ended September 30, 2017, the Company reported a smaller than expected consolidated net loss attributable
As we continue to confront the staggering human and economic toll created by opioid abuse and addiction, we're focused on taking actions that reduce the scope of new addiction by decreasing unnecessary exposure to opioids. At the same time, we also must take steps to help those with acute and chronic pain who need access to medicines, including opi
Bangalore- Strides Shasun Limited today announced that it's wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received approval from the United States Food& Drug Administration for Acetazolamide Tablets USP, 125 mg and 250 mg., a generic version of Diamox Tablets. The product, to be launched immediately, will be marketed by Strides Pharma
The "US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report has been added to Research and Markets' offering. The market is projected to reach a value of more than US$ 16 Billion by 2022, growing at a CAGR of around 8% during 2017-2022. The US generic injectables market reached a value of U
Biocon has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, in India. Biocon has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, c
Biosimilars market was valued at US$ 3.52 Bn in 2016, and is expected to reach US$ 25.83 Bn by 2025, expanding at a CAGR of 23.1% from 2017 to 2025.. Biosimilars Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies And Forecasts, 2017 To 2025. Biosimilars Market- Growth, Share, Opport
"Acute Market Reports Logo" Biosimilars market was valued at US$ 3.52 Bn in 2016, and is expected to reach US$ 25.83 Bn by 2025, expanding at a CAGR of 23.1% from 2017 to 2025. Biosimilars Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies And Forecasts, 2017 To 2025. Biosimilars Ma
Samsung Bioepis has claimed the distinction of getting the first biosimilar of Roches $6.8 bn breast cancer blockbuster Herceptin in the EU. Samsung Bioepis development partner for the biosimilar, Merck& Co, will commercialise the drug in Europe under the terms of a collaboration between the two companies agreed in 2013. Herceptin is also facing th
Glenmark Pharmaceuticals Inc., USA has received final approval by the USFDA for HAILEYTM Fe 1/ 20, the generic version of Loestrin Fe 1/ 20 Tablets, of Allergan Pharmaceuticals International Limited. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the g
A leading full-service global consulting firm specializing in serialization and traceability, as well as supply chain strategy and operational transformation programs and Medicines for Europe, an organization serving as the voice of Europes generic, biosimilar and value-added medicines industries, will co-host a Pharma CMO Summit on December 4-5,..
-Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced it has received approval of the Companys abbreviated new drug application from the U.S. Food and Drug Administration of Hydrocortisone Butyrate Lotion 0.1%. As we were the first ANDA applicant to submit an ANDA with a paragraph IV certification for Hydroc
It is an abridged version of the Company s full Half Year report for the six months ended 30 September 2017. The Company's Half Year Report& Accounts for the six months ended 30 September 2017 has been submitted to the UK Listing Authority, and will shortly be available for inspection on the National Storage Mechanism: www.hemscott.com/nsm. do.
Pharmaceutical company Ajanta Pharma has announced the launch of generic Clonidine Hydrochloride extended release tablets in US market by its wholly owned subsidiary Ajanta Pharma USA Inc. The strength of the tablets is 0.1 milligram.
-A new national survey conducted by the Alliance for Safe Biologic Medicines found that Canadian physicians overwhelmingly support distinguishable names for all biologics, including biosimilars. The results of the survey were recently presented at the Drug Information Association Annual Canadian meeting in Ottawa by ASBM's immediate past chairman,.
Avivagen Inc., a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is delighted to welcome Mr. Following his graduation from Western University in 1985, Aubrey joined Novopharm Limited, one of the largest generic drug manufacturers in Canada, in the role of a sales repre
On Monday, Samsung Bioepis announced that it received final approval for the sale of its anti-cancer drug Ontruzant in Europe. The two biggest markets were the United States and Europe. Samsung Bioepis had already succeeded in getting approval to sell three biosimilar drugs in Europe.
Mumbai, India- Cipla Ltd, a global pharmaceutical company, today announced that it has received final approval for its Abbreviated New Drug Application for Decitabine Injection 50 mg single-use sterile vial from the United States Food and Drug Administration to market generic version of Otsuka America Pharmaceutical Inc.' s Dacogen. About Cipla Ltd
The Food and Drug Administration issued guidance Tuesday to push drugmakers to craft cheaper generic painkillers that are more difficult to snort, inject or otherwise abuse than standard opioids. But we also know a significant barrier to use can be price, " Dr. Gottlieb said. Senate Democrats want Mr. Trump to dedicate $45 billion in taxpayer fundi
The Food and Drug Administration is making moves to spur development of generic and cheaper opioids that are difficult to abuse. So far, the FDA has approved 10 abuse-deterrent opioids. However, their uptake has been slow among doctors, according to FDA Commissioner Scott Gottlieb.
Jacobson Pharma Corporation Limited, a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its unaudited interim results of the Company and its subsidiaries for the six months ended 30 September 2017. Gross profit and profit from operations rose by 14.0% to